產品描述: | JNJ-17203212 is a selective, potent and competitive TRPV1 antagonist. JNJ-17203212 is developed for researching pain management, such as migraine |
靶點: |
TRPV1;TRP/TRPVChannel |
體內研究: |
JNJ-17203212 (0.3 mg/kg; i.v.) dose-dependently reduces inflammatory soup (IS)-induced the immediate early gene c-fos expression. JNJ-17203212 completely blocks capsaicin-induced CGRP (the neurotransmitter calcitonin gene-related peptide) release in a dose-dependent manner. Animal Model: Male Sprague-Dawley rats (260-300 g) Dosage: 0.3 mg/kg Administration: Intravenous injection Result: Had a dose-dependent effect on the elevated c-fos expression that occurred after intracisternal injection of IS. |
參考文獻: |
1. Xingjuan Chen, et al. Furanocoumarins are a novel class of modulators for the transient receptor potential vanilloid type 1 (TRPV1) channel.J Biol Chem. 2014 Apr 4; 289(14): 9600-9610. 2. Jannis E Meents, et al. Two TRPV1 receptor antagonists are effective in two different experimental models of migraine. J Headache Pain. 2015; 16: 57. |
溶解性: |
Soluble in DMSO |
保存條件: |
-20℃ |
配置溶液濃度參考: |
|
1mg |
5mg |
10mg |
1 mM |
2.387 ml |
11.933 ml |
23.866 ml |
5 mM |
0.477 ml |
2.387 ml |
4.773 ml |
10 mM |
0.239 ml |
1.193 ml |
2.387 ml |
50 mM |
0.048 ml |
0.239 ml |
0.477 ml |
|
注意: |
部分產品我司僅能提供部分信息,我司不保證所提供信息的權威性,僅供客戶參考交流研究之用。 |